Reuters: Regulatory News: RPT-GSK files melanoma drug combination early in race to market

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

RPT-GSK files melanoma drug combination early in race to market Jul 9th 2013, 07:11 Tue Jul 9, 2013 3:11am EDT LONDON, July 9 (Reuters) - GlaxoSmithKline has filed for U.S. approval of a two-drug combination against melanoma earlier than many industry analysts expected, using data from a mid-stage clinical trial. The move highlights a growing belief among drug companies that highly specific cancer drugs can prove their worth after relatively small-scale testing, speeding their path to market. Britain's biggest pharmaceuticals group said on Tuesday it had submitted the combination of dabrafenib and trametinib to the U.S. Food and Drug Administration based on data from a randomised Phase I/II study. Many investors had expected GSK to wait until it had received final-stage Phase III data on the drug combination, results of which are not due to come in until towards the end of this year. The FDA gave a green light in May for the two drugs to be used separately. Both drugs are given as pills and are marketed under the brand names Tafinlar and Mekinist. Tafinlar, or dabrafenib, belongs to a class of cancer drugs called BRAF inhibitors, while Mekinist, or trametinib, inhibits a protein associated with cancerous tumours known as MEK. Together they are expected to produce a more effective and sustained treatment for melanoma, and combining them is seen as the main commercial opportunity for the medicines.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions